NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

1,151

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

May 19, 2025

Study Completion Date

May 19, 2025

Conditions
HER2-negative
Trial Locations (31)

1112

Research Site, Quezon City

10330

Research Site, Bangkok

10400

Research Site, Bangkok

10700

Research Site, Bangkok

47500

Research Site, Kaula Lumpur

Research Site, Subang Jaya

59100

Research Site, Subang Jaya

110005

Research Site, Delhi

110029

Research Site, Delhi

110085

Research Site, Delhi

160055

Research Site, Mohali

168583

Research Site, Singapore

221005

Research Site, Varanasi

229899

Research Site, Singapore

258499

Research Site, Singapore

308433

Research Site, Singapore

400012

Research Site, Mumbai

500034

Research Site, Hyderabad

560017

Research Site, Bengaluru

682041

Research Site, Kochi

751003

Research Site, Bhubaneshwar

Unknown

Research Site, Rosario

Research Site, São Paulo

Research Site, Santo Domingo

Research Site, Hong Kong

Research Site, Jakarta

Research Site, Mexico City

Research Site, Panama City

Research Site, Hanoi

Research Site, Ho Chi Minh City

Research Site, Huế

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06131424 - NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter